
Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

BioSpain breaking records
On its 20th anniversary in Catalonia’s vibrant capital Barcelona, BioSpain 2023 is set to break records in terms of attracting visitors,...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

French team BioAroma awarded with BISC-E 2023 prize
In front of around 200 invited guests, the French team received the cash prize for first place in the BISC-E 2023 competition and a one-year free BIC...

UK boosts AMR defenses with £30m PACE initiative
By bringing together funding, resources, and partnerships from its three notable partners Innovate UK, LifeArc, and Medicines Discovery Catapult...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Recordbreaking BIO-Europe in Munich, but: back to 2019
Record figures and a much better mood in Europe than one is currently hearing from the USA. Financing is difficult at the moment and the US...